Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos compuestos para el tratamiento de enfermedades del sistema nervioso central


Oferta Tecnológica
Un instituto público español de investigación ha obtenido nuevos compuestos antagonistas de los canales de calcio dependientes de voltaje, que se utilizan para controlar los niveles de calcio en las neuronas porque pueden regular la sobrecarga de calcio descrita en diversas patologías del sistema nervioso (Alzheimer, Parkinson, esclerosis lateral amiotrófica, ictus, dolor y epilepsia). Estos compuestos presentan un perfil neuroprotector en neuronas y tejidos nerviosos sometidos a estímulos tóxicos relacionados con la neurodegeneración. Se buscan compañías biofarmacéuticas con el fin de establecer acuerdos de licencia o joint venture.


New compounds for the treatment of central nervous system diseases
A Spanish health research institute has obtained new voltage-dependent calcium channel antagonist compounds, useful for the control of cell calcium levels in neurons, as these compounds can regulate the calcium overload described in several pathologies of the nervous system (Alzheimer, Parkinson, Amyothrophyc Lateral Esclerosis, Stroke, Pain and Epilepsia). They are looking for biopharmaceutical companies for license or joint venture agreement.
The alteration of cytosolic calcium levels in neurons triggers excitotoxicity-induced cell death mechanisms and the subsequent neurodegeneration. The control of such intracellular calcium by drugs blocking voltage-gated calcium channels (VGCC) is one of the most common therapeutic strategies to treat cardiovascular diseases like hypertension, angina or arrhythmia. Thus, the so-called calcium-antagonists act in the circulatory system by reducing the calcium influx through these channels, which are exclusively the L-type VGCC. But this pharmacological activity has hindered their use in other therapies, like those from the central nervous system (CNS), though the blockade of VGCC has been promising target in in vitro models of neurodegenerative diseases, like Alzheimer´s or Parkinson´s, as well as stroke, whereby the neuronal death occurs initially via massive calcium entry stimulated by high exposure to the excitatory neurotransmitter glutamate.
One alternative to avoid cardiovascular side effects would be the design of VGCC blockers unable to interact with peripheral L-type channels. Unfortunately, there are very few examples of selective drugs lacking effect on L-type VGCC, and mainly based in peptidomimetis or peptides toxins (e.g. ziconotide).
On this sense, the Spanish health research institute has identified about twenty compounds related to the natural product gramine that showed a decent blockade of the increase of cytosolic calcium stimulated by depolarization in cells.
So they offer small-sized drugs that block non-L-type VGCC selectively, and also clarify the role of different calcium channels (P/Q and N-type) in the physiological and pathological processes where they have been implicated in CNS diseases.
They are looking for partners, mainly biotechnological of biopharmaceutical companies that could be interested in license in the compounds in order to increase their product portfolio, and continue the development of them. Also could be possible a joint venture agreement as the research group could provide more products or developments on demand of the other partners.
Advantages and Innovations:
These compounds show neuroprotective profile in neurons and nerve tissues subjected to toxic stimulus related to neurodegeneration. The best compound has demonstrated it is a non-L-type calcium channel blocker.
Stage of Development:
Under development/lab tested
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application in priority

Partner sought

Type and Role of Partner Sought:
They are looking for biotechnological or biopharmaceutical companies interested in licence in the products or to jointly develop new products or therapies for CNS pathologies.


Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
06002001 Bioquímica / biofísica
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos